Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pulmonology
Volume 2016, Article ID 2359437, 4 pages
http://dx.doi.org/10.1155/2016/2359437
Case Report

Severe Acute Pulmonary Toxicity Associated with Brentuximab in a Patient with Refractory Hodgkin’s Lymphoma

1Division of General Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
2Division of Medical Education, Paul L. Foster School of Medicine and Texas Tech University HSC, El Paso, TX 79905, USA
3School of Medicine, Universidad Autonoma de Tamaulipas (UAT), Tampico, Mexico
4Division of Hematology and Oncology, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
5Division of Pulmonary and Critical Care Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA

Received 7 January 2016; Accepted 31 March 2016

Academic Editor: Tun-Chieh Chen

Copyright © 2016 Yasmin Sabet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Acute pulmonary toxicity associated with brentuximab appears to be a rare but serious adverse effect that can be potentially fatal. We report the case of a twenty-nine-year-old female with Hodgkin’s lymphoma who was treated with brentuximab and later presented with severe acute pulmonary toxicity; she improved after the discontinuation of brentuximab and administration of antibiotics and glucocorticoid therapy. Currently there is very little data in the literature in regard to the clinical manifestations and characteristics of patients taking brentuximab and the potential development of acute severe pulmonary toxicity, as well as the appropriate therapeutic approach, making this particular case of successful treatment and resolution unique.